Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + FOLFOXIRI Dose Escalation in mCRC
NCT00422773Phase 2
Key facts
- Status
- Completed
- Start
- Jan 2007
- Primary completion
- Jun 2008
- Countries
- 1
- Sponsor
- Technische Universität Dresden
- Modality
- Monoclonal Antibodies
- Drugs
- KL-140
- Conditions
- metastatic colorectal cancer (mCRC)
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in metastatic colorectal cancer (mCRC), sponsored by Technische Universität Dresden. Primary endpoints: Maximum Tolerated Dose and Safety. Started Jan 2007; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Cetuximab + FOLFOXIRI
Cetuximab combined with Irinotecan, Oxaliplatin, 5-FU, and Folinic Acid.
03
Who it enrols
Patients with non-resectable, histologically confirmed metastatic colorectal cancer (EGFR-positive or negative), WHO performance status 0-1, and adequate organ function. Excludes prior EGFR-targeting therapy or chemotherapy for metastatic disease.
04
Endpoints
Primary
Maximum Tolerated Dose
Safety
Secondary
Feasibility
Toxicity
Overall Response Rate
Resection Rate
Progression-Free Survival
Overall Survival
Beyond the preview
Go deeper on NCT00422773.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00422773.